RFLSP project opens the Russian life science market for the global partnerships - Russian-Finnish Life Science Park | Российско-Финский парк живых систем

In the framework of the project Russian-Finnish Life Science Park complex research of the Russian life science industry was developed in order to ensure the development of international cooperation between Russian, Finnish and EU SME companies in the sphere of life science and biotechnology.

In the last few years, including the dramatic for the global economy year 2020, the Russian pharmaceutical and biotechnology industry has shown stable positive dynamics and can be considered as one of the drivers of innovative development of the national economy and healthcare. Pharmaceutical production indices of the Russian Federation in 2019-2020 showed growth in terms of the production of pharmaceutical substances as well as that of drugs and materials used for medical purposes. Russian pharmaceutical market in the period from 2016 to 2019 grew annually by an average of 6.6% in ruble terms, with an even higher increase in 2020 – 9.8%.
At the same time, in the global pharmaceutical market, the share of the Russian market, one of the top ten pharmaceutical markets worldwide, is relatively small – about 2.2%. In terms of sales per capita, Russia ranks only 30th in the world. Despite the fact that the Russian pharmaceutical industry is currently underrepresented in international markets, Russian enterprises are consistently increasing their export volumes, thus creating good base for further growth.

Strong dependence on imports is one of the key features of the Russian pharmaceutical market: more than 80% of Russian drugs are currently produced using imported substances. At the same time, in 2020, the industry demonstrated a decrease in imports along with an increase in the export of pharmaceutical products.

According to the draft of the Strategy for the Development of the Pharmaceutical Industry "Pharma-2030" (currently under development), the projected market capacity, taking into account the financial and economic situation, may amount to RUB 5 trillion by 2030 in consumer prices, while the volume of export of medicines, in case of implementation of support measures, may reach USD 3,800 million. The achievement of this ambitious goal may be facilitated by such factors as expiration in 2019-2022 of patent protection terms for many original biological products, as well as the development of the segment of innovative drugs in narrow therapeutic niches.
The developed research consists of two parts. The first part includes detailed industry overview and describes key market trends in Russia and Leningrad region, provides information about fundamental educational and scientific institutions that educate specialists and conduct advanced studies in pharmaceutical sphere. Besides, the document includes information about key clusters and associations and provides calendar of key national and international industry events that are offering opportunities for experience exchange and business matchmaking. The second part of research includes database of over 50 leading companies in the pharmaceutical industry on the Russian market.

Content of the report

    • Industry overview
    • Key trends
    • Educational institutions
    • Scientific institutions
    • Events 
    • Clusters and associations 
    • Cases and success stories
    • Information sources

Browse the report

2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

Interested in details? Download the full report now!

Available downloads: Russian-Finnish Life Science Industry - Research & export directort

*The project is funded by the European Union, the Russian Federation and the Republic of Finland in the framework of South-East Finland-Russia CBC 2014-2020 Programme. The project is executed by Saint Petersburg Technopark (RUS) (Lead partner) and Municipality of the city of Kotka (FIN).

Follow us